Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

Y0001516

Rivastigmine hydrogen tartrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H22N2O2 · C4H6O6
Numéro CAS:
129101-54-8
Poids moléculaire :
400.42
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

rivastigmine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

Clé InChI

GWHQHAUAXRMMOT-RWALOXMOSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001485

Rivastigmine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001515

Rivastigmine impurity D, European Pharmacopoeia (EP) Reference Standard

1604811

Rivastigmine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1604836

Rivastigmine, United States Pharmacopeia (USP) Reference Standard

1604825

Rivastigmine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1604847

Rivastigmine tartrate R-isomer, United States Pharmacopeia (USP) Reference Standard

1604869

Rivastigmine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1604858

Rivastigmine tartrate, United States Pharmacopeia (USP) Reference Standard

1604870

Rivastigmine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1604961

Rivastigmine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1604950

Rivastigmine Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR2034

Rivastigmine Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2032

Rivastigmine Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2031

Rivastigmine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2029

Rivastigmine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2033

Rivastigmine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2030

Rivastigmine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbonesEnvironment
GHS06,GHS09

Mention d'avertissement

Danger

Mentions de danger

H300 - H411

Classification des risques

Acute Tox. 2 Oral - Aquatic Chronic 2

Code de la classe de stockage

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Cassandra Richardson et al.
International journal of geriatric psychiatry, 28(12), 1312-1317 (2013-04-16)
A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of AChEIs on blood
Zhen-Zhen Yang et al.
International journal of pharmaceutics, 452(1-2), 344-354 (2013-05-18)
Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated with cholinergic neurons degeneration. The blood-brain barrier (BBB) not only provides protection for the brain but also hinders the treatment and diagnosis of this neurological disease, because the drugs must
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique